The Effect of Pomegranate (Punica Granatum L.) Peel Compress Application on Pain and Physical Function Status

The Effect of Pomegranate (Punica Granatum L.) Peel Compress Application on Pain and Physical Function Status in Patients With Knee Osteoarthritis

Osteoarthritis is the most common type of arthritis among rheumatologic diseases. Complementary therapies are one of the effective methods for pain control. This study was planned as a randomized controlled experimental study. For this purpose, patients diagnosed with knee osteoarthritis who applied to the Orthopedics Outpatient Clinic will be included. It was calculated that the study would include at least 67 patients. The study will be collected using patient information form, descriptive characteristics form, Visual Analog Scale (VAS) and WOMAC osteoarthritis application scale. It was planned as a randomized controlled experimental study to evaluate the effect of pomegranate peel (P. granatum) compress application on pain and function status. The study was divided into 3 groups as Pomegranate (Punica granatum) peel compress, hot compress and control group. Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.

This randomized controlled experimental study was conducted to evaluate the effect of pomegranate (Punica granatum) peel compress application on pain, stiffness and physical function in individuals with knee osteoarthritis.

Inclusion Criteria:

• Visual analog scale score of 3 and above,
• those aged 45 and over,
• Diagnosed with knee OA by a physician according to the criteria of the American - Rheumatology Association (ARD),
• pain lasting at least 1 month or longer,
• not included in any physical therapy program during the research period, a
• capable of answering research questions,
• agreeing to participate in the research by giving verbal and written consent

Exclusion Criteria:

• with a defined psychiatric illness,
• having vision and hearing problems,
• diagnosed with complex disease such as malignant,
• having a wound in the application area,
• with a diagnosed vascular disease,
• the patient's other inflammatory disease such as rheumatoid arthritis, gout, fibromyalgia
• who have had serious trauma or surgery in the last 6 months,
• who have received DMARDS or intra-articular steroid injection therapy in the last 3 months